ArticleDrug design, development and therapy2025

Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer.

Zeyu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.